Teva walloped $163M in hepC ruling, doc 'unfit' for trial
October 12, 2011 — 11:32am ET | By George Miller
The other shoe has dropped for Teva ($TEVA) and supply chain partners Baxter ($BAX) and McKesson ($MCK) in the case of a hepatitis C outbreak that followed reuse of jumbo-sized vials of propofol at a colonoscopy center. The jury assessed $162.5 million in punitive damages on top of the $20.1 million in compensatory damages it awarded last week to three victims, reports Bloomberg.
October 12, 2011 — 11:32am ET | By George Miller
The other shoe has dropped for Teva ($TEVA) and supply chain partners Baxter ($BAX) and McKesson ($MCK) in the case of a hepatitis C outbreak that followed reuse of jumbo-sized vials of propofol at a colonoscopy center. The jury assessed $162.5 million in punitive damages on top of the $20.1 million in compensatory damages it awarded last week to three victims, reports Bloomberg.